Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 14, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-021-01115-0
Keywords
Adoptive T-cell receptor-based therapy; Human leukocyte antigen typing; Biomarker screening; Lymphodepletion; Clinical trials; Solid tumors
Categories
Funding
- Jamie's Hope
- National Institutes of Health/National Cancer Institute [P30 CA016672]
Ask authors/readers for more resources
TCR-based adoptive therapy uses genetically modified lymphocytes to target specific tumor markers, but faces challenges with TCR product manufacturing, patient selection, and preparation for lymphodepletion. Overcoming these challenges and developing next-generation strategies are crucial for improving the efficacy and safety of TCR-based therapies. Optimization of technology for TCR product generation and patient monitoring for adverse events is necessary.
T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced TCR product, lymphodepletion, and infusion of the TCR-based adoptive therapy. In this review, we summarize the current technology and early clinical development of TCR-based therapy in patients with solid tumors. The challenges of TCR-based therapy include those associated with TCR product manufacturing, patient selection, and preparation with lymphodepletion. Overcoming these challenges, and those posed by the immunosuppressive microenvironment, as well as developing next-generation strategies is essential to improving the efficacy and safety of TCR-based therapies. Optimization of technology to generate TCR product, treatment administration, and patient monitoring for adverse events is needed. The implementation of novel TCR strategies will require expansion of the TCR approach to patients with HLA haplotypes beyond HLA-A*02:01 and the discovery of novel tumor markers that are expressed in more patients and tumor types. Ongoing clinical trials will determine the ultimate role of TCR-based therapy in patients with solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available